期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
A promising leap in early screening for chronic kidney disease:The smartphone-integrated handheld automated biochemical analyzer
1
作者 Ming Chen 《Journal of Pharmaceutical Analysis》 2025年第9期1942-1942,共1页
In the face of the escalating global prevalence of chronic kidney disease(CKD),early diagnosis and effective management have become crucial imperatives[1].The article“Development of a smartphone-integrated handheld a... In the face of the escalating global prevalence of chronic kidney disease(CKD),early diagnosis and effective management have become crucial imperatives[1].The article“Development of a smartphone-integrated handheld automated biochemical analyzer for point-of-care testing of urinary albumin”by Wu et al.[2]presents a novel smartphone-integrated handheld automated biochemical analyzer(sHABA),which offers new possibilities for the early diagnosis and management of CKD,holding great significance for improving patients’health. 展开更多
关键词 biochemical analyzer point care testing urinary albumin smartphone integrated handheld automated biochemical analyzer chronic kidney disease improving pati chronic kidney disease ckd early early screening
暂未订购
Development of the personalized criteria for microscopic review following four different series of hematology analyzer in a Chinese large scale hospital 被引量:10
2
作者 CUI Wei WU Wei +14 位作者 WANG Xin WANG Geng HAO Ying-ying CHEN Yu LUO Dan SHOU Wei-ling ZHANG Shuo XIANG Xue-fang SI Yong-zhen CHEN Qian CAI Hao LI Tan SHEN Han SHANG Kun ZHANG Yong-qiang 《Chinese Medical Journal》 SCIE CAS CSCD 2010年第22期3231-3237,共7页
Background A generally accepted guideline ("41 rules") published by the International Consensus Group for Hematology Review (ICGHR) can not be suitable for all the laboratories because the facility type, laborat... Background A generally accepted guideline ("41 rules") published by the International Consensus Group for Hematology Review (ICGHR) can not be suitable for all the laboratories because the facility type, laboratory requirements, sample volume, review rate, turn around time, instrument model and characters etc. are quite different from each other, which may cause a higher workload for microscopy review or lead to false or misleading results. Therefore, we decided to develop the personalized review criteria for 4 series of hematology analyzers in the same hospital, and describe all the implement procedures in detail. Methods The total 1770 blood samples were collected from Peking Union Medical College Hospital. Referring to the suggested criteria by international consensus group for hematology review ("41 rules"), the personalized review criteria for 4 series of hematology analyzers including Siemens Advia 2120, Sysmex XE-2100, Sysmex XT-1800i and Sysmex XS-800i were established and validated by adjusting the rules in order to reduce the false positive rate and keep the false negative acceptable by clinical. Results Using the "41 rules", high review rates of 37.94%, 35.56%, 33.44% and 37.94% were got respectively in Siemens Advia 2120, Sysmex XE-2100, Sysmex XT-1800i and Sysmex XS-800i. Three false positive rules mainly were observed in all of 4 analyzers: white blood cell 〈3×10^9/L or 〉30×10^9/L, platelet 〈100×10^9/L or 〉1000×10^9/L and immature granulocyte. Specialized rules were observed in different series of analyzers, atypicaVvariant lymphs flag were found mainly in Sysmex XE-2100, Aniso-RBC were found mainly in Sysmex XT-1800i, flag of "immature granulocyte" mainly in Sysmex XS-800i, Micro-RBC, Macro-RBC and Aniso-RBC mainly in Siemens Advia 2120. Rules of immature granulocyte blast, and NRBC flag would be mainly triggered by hematology malignant tumor. We could not delete these rules due to the risk of false negative of serious disease, other rules were deleted or revised. After continually optimizing to the rules, we finalized the criteria suitable for Siemens Advia 2120, Sysmex XE-2100, Sysmex XT-1800i and Sysmex XS-800i in our laboratory. The false negative rates were 2.94%, 2.86%, 3.10% and 2.78%, the review rates were 31.07%, 30.00%, 30.01% and 30.09%, and there was no hematology malignant tumor missed. Validated by 547 samples, the false negative rates of our optimized rules were 0.37%, 0.55%, 0.55%, and 0.91% respectively. Conclusion The criteria can be based on the criteria established by International Consensus Group for Hematology Review but must be optimized according to the different requirements. 展开更多
关键词 complete blood count microscopy review CRITERIA automated hematology analyzer
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部